Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30899633 | 1.00 | GAA (0.56) | GAALMNAEPHX2HTTALDH1A1 | |
| SCHEMBL30089037 | 1.00 | GAA (0.56) | GAALMNAEPHX2HTTALDH1A1 | |
| SCHEMBL30098447 | 0.94 | EPHX2 (0.58) | GAALMNAEPHX2HTTALDH1A1 | |
| SCHEMBL28932946 | 0.94 | EPHX2 (0.58) | GAALMNAEPHX2HTTALDH1A1 | |
| SCHEMBL30098558 | 0.94 | EPHX2 (0.58) | GAALMNAEPHX2HTTALDH1A1 | |
| SCHEMBL23951732 | 0.94 | EPHX2 (0.58) | GAALMNAEPHX2HTTALDH1A1 | |
| SCHEMBL28932952 | 0.94 | EPHX2 (0.58) | GAALMNAEPHX2HTTALDH1A1 | |
| SCHEMBL27177201 | 0.85 | GAA (0.57) | GAALMNAEPHX2HTTALDH1A1 | |
| SCHEMBL30679668 | 0.84 | USP30 (0.50) | POLBKDM4E | |
| SCHEMBL29136079 | 0.84 | USP30 (0.50) | POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360126-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2024-10-31 | — | — | US | disclosed |
| EP-4405051-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023046806-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360126-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | SSB, TPMT, KCNB2 | GAA 3447/4885LMNA 3525/4885EPHX2 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.